The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer

Kosei Hasegawa, Takafumi Nakamura, Mary Harvey, Yasuhiro Ikeda, Ann Oberg, Mariangela Figini, Silvana Canevari, Lynn C. Hartmann, Kah Whye Peng

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


Purpose: Attenuated measles viruses are promising experimental anticancer agents currently being evaluated in a phase I dose escalation trial for ovarian cancer patients. Virus attachment, entry, and subsequent intercellular fusion between infected and uninfected neighboring cells are mediated via the two measles receptors (CD46 and SLAM). To minimize potential toxicity due to measles virus - associated immunosuppression and infection of nontarget tissues, we sought to develop an ovarian cancer exclusive fully retargeted measles virus. Experimental Design and Results: Interactions of measles virus with its natural receptors were ablated, and a single-chain antibody (scFv) specific for α-folate receptor (FRα), a target overexpressed on 90% of nonmucinous ovarian cancer, was genetically engineered on the viral attachment protein (MV-αFR). Specificity of virus tropism was tested on tumor and normal cells. Biodistribution of measles virus infection was evaluated in measles-susceptible CD46 transgenic mice, whereas antitumor activity was monitored noninvasively by bioluminescence imaging in xenograft models. Tropism and fusogenic activity of MV-aFR was redirected exclusively to FRα without compromise to virus infectivity. In contrast to the parental virus, MV-αFR has no background infectivity on normal human cells. The antitumor activity of MV-αFR, as assessed by tumor volume reduction and overall survival increase, was equal to the parental virus in two models of human ovarian cancer (s.c. and i.p.). Conclusions: A FR-exclusive ovarian cancer targeted oncolytic virus was generated and shown to be therapeutically effective, thus introducing a new modality for FR targeting and a candidate measles virus for clinical testing.

Original languageEnglish (US)
Pages (from-to)6170-6178
Number of pages9
JournalClinical Cancer Research
Issue number20 PART 1
StatePublished - Oct 15 2006

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer'. Together they form a unique fingerprint.

Cite this